KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Thermo Fisher Scientific (TMO) over the last 17 years, with Sep 2025 value amounting to $2.0 billion.

  • Thermo Fisher Scientific's Cash & Equivalents fell 57.33% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 57.33%. This contributed to the annual value of $4.0 billion for FY2024, which is 50.37% down from last year.
  • As of Q3 2025, Thermo Fisher Scientific's Cash & Equivalents stood at $2.0 billion, which was down 56.69% from $4.6 billion recorded in Q2 2025.
  • In the past 5 years, Thermo Fisher Scientific's Cash & Equivalents registered a high of $12.0 billion during Q4 2021, and its lowest value of $1.9 billion during Q3 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $4.6 billion (2025), whereas its average is $4.8 billion.
  • As far as peak fluctuations go, Thermo Fisher Scientific's Cash & Equivalents plummeted by 75.73% in 2022, and later surged by 125.76% in 2024.
  • Thermo Fisher Scientific's Cash & Equivalents (Quarterly) stood at $4.5 billion in 2021, then surged by 90.40% to $8.5 billion in 2022, then dropped by 5.24% to $8.1 billion in 2023, then tumbled by 50.37% to $4.0 billion in 2024, then crashed by 57.33% to $2.0 billion in 2025.
  • Its Cash & Equivalents was $2.0 billion in Q3 2025, compared to $4.6 billion in Q2 2025 and $4.1 billion in Q1 2025.